NASDAQ:RYTM Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free RYTM Stock Alerts $38.28 +0.13 (+0.34%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$37.40▼$38.8950-Day Range$38.01▼$49.2352-Week Range$15.50▼$52.57Volume305,047 shsAverage Volume473,855 shsMarket Capitalization$2.30 billionP/E RatioN/ADividend YieldN/APrice Target$47.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Rhythm Pharmaceuticals alerts: Email Address Rhythm Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside23.3% Upside$47.20 Price TargetShort InterestBearish16.96% of Shares Sold ShortDividend StrengthN/ASustainability-1.80Upright™ Environmental ScoreNews Sentiment0.29Based on 5 Articles This WeekInsider TradingSelling Shares$7.63 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.05) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.40 out of 5 starsMedical Sector442nd out of 913 stocksPharmaceutical Preparations Industry190th out of 420 stocks 2.5 Analyst's Opinion Consensus RatingRhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRhythm Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted16.96% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRhythm Pharmaceuticals has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.Change versus previous monthShort interest in Rhythm Pharmaceuticals has recently increased by 4.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRhythm Pharmaceuticals does not currently pay a dividend.Dividend GrowthRhythm Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRhythm Pharmaceuticals has received a 63.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Anti-obesity medication (A08)", "Clinical research services for deficiency diseases", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Rhythm Pharmaceuticals is -1.80. Previous Next 1.8 News and Social Media Coverage News SentimentRhythm Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Rhythm Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,626,355.00 in company stock.Percentage Held by InsidersOnly 4.70% of the stock of Rhythm Pharmaceuticals is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.05) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rhythm Pharmaceuticals is -11.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rhythm Pharmaceuticals is -11.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRhythm Pharmaceuticals has a P/B Ratio of 13.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIA new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… Click here to see me place one of these trades LIVE on camera. About Rhythm Pharmaceuticals Stock (NASDAQ:RYTM)Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Read More RYTM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RYTM Stock News HeadlinesApril 4, 2024 | insidertrades.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Christopher Paul German Sells 368 SharesMarch 28, 2024 | marketbeat.com7 Stocks That Will Drive the Weight Loss Drugs Market (RYTM)The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.April 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 24, 2024 | globenewswire.comRhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024April 20, 2024 | americanbankingnews.comWells Fargo & Company Lowers Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $52.00April 16, 2024 | globenewswire.comRhythm Pharmaceuticals Announces New Employment Inducement GrantsApril 14, 2024 | finance.yahoo.comMarket Sentiment Around Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)April 11, 2024 | yahoo.comRhythm and Autism comes to Fertile Ground FestivalApril 27, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… April 10, 2024 | markets.businessinsider.com5 Analysts Assess Rhythm Pharmaceuticals: What You Need To KnowApril 10, 2024 | msn.comLee Brice coming to Rhythm City CasinoApril 9, 2024 | msn.comHendersonville's 2024 Rhythm and Brews lineup announcedApril 8, 2024 | msn.comRising Chorus: Rachana Shah and Rhythm Wagholikar’s Anthem for Prime Minister ModiApril 4, 2024 | msn.comHeadbangers: Rhythm Royale - Official Battle of the Dancers & Season 3 Launch TrailerApril 2, 2024 | msn.comRick Springfield to play Rhythm City in JulyApril 1, 2024 | globenewswire.comRhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock FinancingMarch 25, 2024 | globenewswire.comRhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific AgonistMarch 23, 2024 | msn.comWatch: Singing dog Nova with "voice of an angel" performs Rhythm of the Night at RSPCA Sheffield shelterMarch 22, 2024 | yahoo.comBongee Bear and the Kingdom of Rhythm Streaming: Watch & Stream Online via Amazon Prime VideoMarch 22, 2024 | finance.yahoo.comChief Technical Officer Joseph Shulman Sells 18,235 Shares of Rhythm Pharmaceuticals Inc (RYTM)March 22, 2024 | msn.comRhythm City welcomes Banda MagueyMarch 20, 2024 | finance.yahoo.comInsider Sell: CFO Hunter Smith Sells 15,515 Shares of Rhythm Pharmaceuticals Inc (RYTM)March 20, 2024 | finance.yahoo.comInsider Sell: Chief Technical Officer Joseph Shulman Sells 15,515 Shares of Rhythm ...March 20, 2024 | finance.yahoo.comInsider Sell: Rhythm Pharmaceuticals Inc (RYTM) CEO David Meeker Disposes of 45,494 SharesMarch 19, 2024 | msn.comRhythm City, Davenport, will bloom with Gin Blossoms alt rockMarch 16, 2024 | finance.yahoo.comRYTM Dec 2024 40.000 putMarch 16, 2024 | finance.yahoo.comRYTM Apr 2024 70.000 callSee More Headlines Receive RYTM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/26/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RYTM CUSIPN/A CIK1649904 Webwww.rhythmtx.com Phone(857) 264-4280Fax857-264-4299Employees226Year FoundedN/APrice Target and Rating Average Stock Price Target$47.20 High Stock Price Target$55.00 Low Stock Price Target$27.00 Potential Upside/Downside+23.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,680,000.00 Net Margins-238.50% Pretax Margin-237.79% Return on Equity-96.02% Return on Assets-55.02% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.43 Sales & Book Value Annual Sales$77.43 million Price / Sales29.73 Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book13.34Miscellaneous Outstanding Shares60,140,000Free Float57,313,000Market Cap$2.30 billion OptionableOptionable Beta1.90 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. David P. Meeker M.D. (Age 70)Chairman, President & CEO Comp: $1.17MMr. Hunter C. Smith M.B.A. (Age 55)CFO & Treasurer Comp: $692.2kMr. Joseph Shulman (Age 49)Chief Technical Officer Comp: $608.2kMr. Yann Mazabraud (Age 51)Executive VP & Head of International Comp: $747.43kMs. Jennifer Lee (Age 48)Executive VP & Head of North America Comp: $644.2kMr. Christopher German (Age 53)Corporate Controller, Principal Accounting Officer & Executive Director Mr. David ConnollyHead of Investor Relations & Corporate CommunicationsMr. Jim FlahertySenior VP & General CounselMs. Sarah RyanVice President of Sales & MarketingMs. Pamela J. Cramer (Age 50)Chief Human Resources Officer More ExecutivesKey CompetitorsMerusNASDAQ:MRUSCorcept TherapeuticsNASDAQ:CORTArvinasNASDAQ:ARVNIndiviorNASDAQ:INDVJanux TherapeuticsNASDAQ:JANXView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 3,600 shares on 4/25/2024Ownership: 0.000%Assenagon Asset Management S.A.Sold 15,985 shares on 4/24/2024Ownership: 0.475%ZRC Wealth Management LLCBought 1,571 shares on 4/19/2024Ownership: 0.003%Hennion & Walsh Asset Management Inc.Bought 20,259 shares on 4/17/2024Ownership: 0.145%Christopher Paul GermanSold 368 sharesTotal: $15,367.68 ($41.76/share)View All Insider TransactionsView All Institutional Transactions RYTM Stock Analysis - Frequently Asked Questions Should I buy or sell Rhythm Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RYTM shares. View RYTM analyst ratings or view top-rated stocks. What is Rhythm Pharmaceuticals' stock price target for 2024? 5 analysts have issued 12-month target prices for Rhythm Pharmaceuticals' stock. Their RYTM share price targets range from $27.00 to $55.00. On average, they predict the company's stock price to reach $47.20 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts. How have RYTM shares performed in 2024? Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of 2024. Since then, RYTM stock has decreased by 16.7% and is now trading at $38.28. View the best growth stocks for 2024 here. When is Rhythm Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our RYTM earnings forecast. How can I listen to Rhythm Pharmaceuticals' earnings call? Rhythm Pharmaceuticals will be holding an earnings conference call on Tuesday, May 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Rhythm Pharmaceuticals' earnings last quarter? Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) released its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.70). The business earned $24.23 million during the quarter, compared to analysts' expectations of $25.38 million. Rhythm Pharmaceuticals had a negative net margin of 238.50% and a negative trailing twelve-month return on equity of 96.02%. The firm's quarterly revenue was up 175.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.75) EPS. What ETFs hold Rhythm Pharmaceuticals' stock? ETFs with the largest weight of Rhythm Pharmaceuticals (NASDAQ:RYTM) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), ALPS Medical Breakthroughs ETF (SBIO), BlackRock Future Health ETF (BMED), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Harbor Corporate Culture Small Cap ETF (HAPS), iShares Micro-Cap ETF (IWC) and Principal Healthcare Innovators ETF (BTEC). What other stocks do shareholders of Rhythm Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT). When did Rhythm Pharmaceuticals IPO? Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager. Who are Rhythm Pharmaceuticals' major shareholders? Rhythm Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.47%), Hennion & Walsh Asset Management Inc. (0.14%), Simplex Trading LLC (0.00%) and ZRC Wealth Management LLC (0.00%). Insiders that own company stock include Christopher Paul German, David P Meeker, Hunter C Smith, Jennifer Chien, Jennifer Kayden Lee, Joseph Shulman, Pamela J Cramer, William T Roberts and Yann Mazabraud. View institutional ownership trends. How do I buy shares of Rhythm Pharmaceuticals? Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RYTM) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
